文献速递消化内镜

胰高血糖素样肽-1受体激动剂使用与接受胃肠镜患者胃残余内容物及误吸风险:系统评价与Meta分析

Glucagon-like peptide-1 receptor agonist use and the risk of residual gastric contents and aspiration in patients undergoing GI endoscopy: a systematic review and a meta-analysis.
PubMed 文献 · Gastrointest Endosc · 2024-12-16

该系统评价与Meta分析纳入23项观察性研究共262018例患者,比较使用与未使用胰高血糖素样肽-1受体激动剂(GLP-1RA)者接受内镜的不良事件风险。GLP-1RA使用者胃残余内容物(OR 4.54,95%CI 3.30-6.24)和提前终止内镜(OR 4.54,95%CI 3.05-6.75)风险显著增加,误吸性肺炎风险无显著差异(OR 0.96,95%CI 0.53-1.75)。同日行胃镜和结肠镜较单行胃镜可显著降低胃残余内容物风险(OR 0.28,95%CI 0.22-0.36)。

要点

  • GLP-1RA使用者胃残余内容物风险显著升高(OR 4.54)。
  • GLP-1RA使用者提前终止内镜风险显著升高(OR 4.54)。
  • 误吸性肺炎风险在GLP-1RA使用者与未使用者间无显著差异。

核心结论

  • GLP-1RA使用与胃残余内容物和提前终止内镜风险增加相关,但接受内镜患者的误吸性肺炎风险无显著差异。

研究设计与样本

  • 系统评价与Meta分析(PROSPERO注册号CRD42024556732),检索PubMed、Scopus、Web of Science、Cochrane Central(自建库至2024年7月1日)及EMBASE(1974年至2024年6月28日)。
  • 纳入双臂成人原创研究(观察性研究、随机对照试验),样本量≥20,行食管胃十二指肠镜或内镜,对照臂无GLP-1RA使用。
  • 排除单臂研究及对照臂在操作前使用过GLP-1RA的研究。
  • 共纳入23项观察性研究,262018例患者。
  • 采用随机效应模型合并效应量。

主要发现

  • GLP-1RA使用者胃残余内容物风险显著增加(OR 4.54,95%CI 3.30-6.24,P<.00001,I²=68%)。
  • GLP-1RA使用者提前终止内镜风险显著增加(OR 4.54,95%CI 3.05-6.75,P<.00001,I²=0%)。
  • 误吸性肺炎风险无显著差异(OR 0.96,95%CI 0.53-1.75,P=.90,I²=70%)。
  • 同日行胃镜和结肠镜较单行胃镜胃残余内容物风险显著降低(OR 0.28,95%CI 0.22-0.36,P<.00001,I²=0%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are used for type 2 diabetes mellitus and obesity, but safety concerns have been raised for users undergoing GI endoscopy because of retained food and aspiration events. We compared the risk of adverse events for GLP-1RA users and nonusers undergoing endoscopy. METHODS: We conducted a systematic review and meta-analysis (PROSPERO registration: CRD42024556732). A systematic search in PubMed, Scopus, Web of Science, and Cochrane Central was performed from their inception until July 1, 2024 (EMBASE from 1974 to June 28, 2024). Double-arm adult human original studies (observational, randomized controlled trial) with a sample size of ≥20 undergoing EGD or endoscopy with no GLP-1RA use in the control arm were searched. Studies were excluded if they were single arm and had any use of GLP-1RA before the procedure in the control arm. Residual gastric contents (RGCs), aspiration pneumonia, and premature endoscopy termination were the main outcomes. The random-effects model was used to pool and get final effect estimates. RESULTS: Twenty-three observational studies were selected consisting of 262,018 patients. GLP-1RA users had a statistically significant increase in the risk of RGCs (odds ratio [OR], 4.54; 95% confidence interval [CI], 3.30-6.24; P < .00001, I2 = 68%) and premature endoscopy termination (OR, 4.54; 95% CI, 3.05-6.75; P < .00001, I2 = 0%). There was no significant difference in the risk of aspiration pneumonia (OR, .96; 95% CI, .53-1.75; P = .90, I2 = 70%). A significant reduction was seen in RGCs when EGD and colonoscopy (OR, .28; 95% CI, .22-.36; P < .00001, I2 = 0%) were done the same day versus EGD alone. CONCLUSIONS: GLP-1RA use was associated with an increased risk of RGCs and premature endoscopy termination, but no significant difference was found in the risk of aspiration pneumonia in patients undergoing endoscopy.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Baig MU, Piazza A, Lahooti A, et al. Glucagon-like peptide-1 receptor agonist use and the risk of residual gastric contents and aspiration in patients undergoing GI endoscopy: a systematic review and a meta-analysis. Gastrointest Endosc. 2024. PMID: 39694296. doi:10.1016/j.gie.2024.12.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。